about
Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclastsEffects of Watercress Containing Rutin and Rutin Alone on the Proliferation and Osteogenic Differentiation of Human Osteoblast-like MG-63 CellsBisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary.Strategies of spinal fusion on osteoporotic spine.Hypercalcemia reduces plasma renin via parathyroid hormone, renal interstitial calcium, and the calcium-sensing receptor.Evaluation of the protective effects of curcuminoid (curcumin and bisdemethoxycurcumin)-loaded liposomes against bone turnover in a cell-based model of osteoarthritis.Biomolecular basis of the role of diabetes mellitus in osteoporosis and bone fracturesMechanisms of osteoclast-dependent bone formation.Interleukin-10 inhibits bone resorption: a potential therapeutic strategy in periodontitis and other bone loss diseases.Wnt and the Wnt signaling pathway in bone development and disease.Regulation of hematopoiesis by activators and inhibitors of Wnt signaling from the niche.Perioperative Medical Management of Spine Surgery Patients With Osteoporosis.The Pharmacological Potential of Rutin.Loss of Sfrp2 in the Niche Amplifies Stress-Induced Cellular Responses, and Impairs the In Vivo Regeneration of the Hematopoietic Stem Cell Pool.Highly selective aza-nitrile inhibitors for cathepsin K, structural optimization and molecular modeling.Proteome analysis of human serum proteins adsorbed onto different titanium surfaces used in dental implants.Renin inhibitor aliskiren exerts beneficial effect on trabecular bone by regulating skeletal renin-angiotensin system and kallikrein-kinin system in ovariectomized mice.
P2860
Q26828486-627AACCA-199A-4825-AB63-1A5EABDE9C7FQ34097915-C16CE014-2DBB-43EF-8448-44897A03F5F0Q34440107-E54356BD-C19F-4153-ACE0-8FCE5CE3EDBAQ35171786-07FEF520-D043-418E-8A40-928C28706798Q35216281-F397AEA2-114D-46E3-BDBD-F8CD2D48BE22Q35535372-EA5B2B29-5FF5-486E-A672-7BA0CAC13FA8Q37101614-F96AA5E0-7BBC-47EC-9B18-2FDD25857438Q37414413-9EC12156-5ED6-44F2-A8BA-CB7511BD7AB9Q37626939-9AB4D620-FC4F-41C7-B8AE-6AD1FC8B8A5DQ37724188-E48CB2FF-5D54-401A-A418-4B622058317BQ38194615-E928A49D-4599-4F91-AE16-1025CE5538C0Q38588299-02E646C7-E6E3-4E82-A065-4B047AA52B75Q39201434-FBBAFF99-9FB1-419E-89C8-8F18B6079C0DQ39684912-07A31DCD-8A8F-437A-A6ED-F402A22622F3Q47896150-6E84E681-C5F3-4C35-8A0F-9507B763D041Q51069183-81EFCD57-74E0-41ED-9851-490BCEA9952AQ53814713-A196CB5A-3CB2-46BA-8835-F3FED5BA3398
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New treatment targets in osteoporosis.
@en
New treatment targets in osteoporosis.
@nl
type
label
New treatment targets in osteoporosis.
@en
New treatment targets in osteoporosis.
@nl
prefLabel
New treatment targets in osteoporosis.
@en
New treatment targets in osteoporosis.
@nl
P1433
P1476
New treatment targets in osteoporosis.
@en
P2093
Sophie Roux
P304
P356
10.1016/J.JBSPIN.2010.02.004
P577
2010-04-08T00:00:00Z